NCT05574673Recruiting
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype - A Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 5 Oct 2022
- Start date
- 1 Dec 2022
- Primary completion date
- 1 May 2028
- Lead sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
- Diseases
- Ovarian cancer
- NCT number
- NCT05574673
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 1 Dec 2022 to the primary completion date, 1 May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Patients are eligible to be included in the study, if all the following inclusion criteria are met:
- Patients with newly diagnosed histologically confirmed epithelial ovarian cancer:
- FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA)
- FIGO stage III-IV of any histology
- Women aged ≥18 years of age at the time of diagnosis
- Patients intended for platinum-based chemotherapy treatment
- Patients capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
- Patients consent to provide archival tumor tissue sample
- Patients are ineligible to be included in the study, if any of the exclusion criteria are met:
- Non-epithelial ovarian cancer, borderline tumors, or mucinous histology
- Patients with FIGO stage I-II, BRCAwt ovarian cancer
Age in the registry: 18 years to 100 years · Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rigshospitalet Coordinator of this site? Confirm its status | København Ø | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.